Answers are grounded in this paper and cite their sources.
We review the drug development of lyso-thermosensitive liposomal doxorubicin (LTLD) which is the first heat-activated formulation of a liposomal drug carrier to be utilized in human clinical trials. This class of compounds is designed to carry a payload of a cytotoxic agent and adequately circulate in order to accumulate at a tumor that is being heated. At the target the carrier is activated by heat and releases its contents at high concentrations. We summarize the preclinical and clinical experience of LTLD including its successes and challenges in the development process.
No takes yet. Share an insight, caveat, or question.
Borys et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: